Warmuth Markus 4
4 · Monte Rosa Therapeutics, Inc. · Filed Jun 25, 2021
Insider Transaction Report
Form 4
Warmuth Markus
DirectorPresident & CEO
Transactions
- Award
Stock Option (Right to Buy)
2021-06-23+141,623→ 141,623 totalExercise: $19.00Exp: 2031-06-22→ Common Stock (141,623 underlying) - Award
Stock Option (Right to Buy)
2021-04-12+538,517→ 538,517 totalExercise: $6.14Exp: 2031-04-12→ Common Stock (538,517 underlying)
Footnotes (4)
- [F1]On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
- [F2]This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
- [F3]25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
- [F4]25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.